AUROPHARMABSEAurobindo Pharma LtdMediumNeutral
Announced Fri, 22 May · 12:35 IST

Intimation of incorporation of a new stepdown subsidiary in France.

Strategic Transactions View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.1%1-day move
₹1549.50
prior close
₹1454.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1-0.1-0.1-6.1-5.9-7.6-8.2-7.3-7.4-9.4-3.5-1.1
Up moveDown movePending
AI summary

Aurobindo Pharma has announced that its wholly owned step-down subsidiary, Agile Pharma BV (Netherlands), has incorporated a new wholly owned subsidiary named Arrow Pharma Production SAS in France. The new entity was incorporated on May 21, 2026, and will operate in the pharmaceuticals sector, focusing on manufacturing generic formulations. Aurobindo Pharma has subscribed to 100% of the share capital by paying 100,000 EUR (100,000 shares at 1 EUR each). The purpose is to expand generic formulation manufacturing operations in France. No government or regulatory approvals were required for this incorporation.

Likely market impact

This is a routine regulatory disclosure and does not directly impact shareholders or stock price in the near term. It represents a routine corporate restructuring as the company expands its manufacturing footprint in Europe through a wholly owned entity.